Concordia Healthcare Corp (TSE:CXR)‘s stock had its “outperform” rating reaffirmed by investment analysts at Royal Bank Of Canada in a report released on Monday, StockTargetPrices.com reports. They currently have a C$18.00 target price on the stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 284.62% from the stock’s previous close.
Several other equities analysts have also recently issued reports on CXR. TD Securities decreased their price target on Concordia Healthcare Corp from C$45.00 to C$37.00 and set a “buy” rating on the stock in a report on Tuesday, June 28th. Goldman Sachs Group Inc. set a C$34.00 price target on Concordia Healthcare Corp in a report on Friday, July 22nd. Finally, CIBC cut Concordia Healthcare Corp from a “sector perform” rating to an “underperform” rating in a report on Monday, August 15th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of C$27.25.
Shares of Concordia Healthcare Corp (TSE:CXR) traded down 4.15% during midday trading on Monday, hitting $4.62. The company had a trading volume of 310,478 shares. The firm’s 50-day moving average is $7.86 and its 200-day moving average is $24.06. Concordia Healthcare Corp has a 12-month low of $4.52 and a 12-month high of $28.35. The firm’s market capitalization is $235.70 million.
Concordia Healthcare Corp Company Profile
Receive News & Ratings for Concordia Healthcare Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia Healthcare Corp and related companies with MarketBeat.com's FREE daily email newsletter.